Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)

China · Delayed Price · Currency is CNY

8.55

-0.18 (-2.06%)

Nov 13, 2026, 3:04 PM CST

SHE:002693 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Revenue	299.73	276.76	174.21	235.93	274.75	320.29
Revenue Growth	38.67%	58.87%	-26.16%	-14.13%	-14.22%	18.87%
Gross Profit	149.35	144.2	89.83	153.52	180.1	232.61
Operating Income	49.01	17.35	-71.77	-36.83	-44.24	-49.62
Net Income	44.01	19.04	-78.3	-50.74	9.01	-20.33
Earnings Per Share	0.12	0.05	-0.19	-0.12	0.02	-0.05
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Other Business	5.78
Production of drugs sales business	247.24
Inter-Segment Elimination	-68.26
Entrusted Business	92
Total	276.76

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Investments	53.67	59.1	45.11	31.9	146.01	77.02
Total Debt	196.69	280.73	276.21	186.05	223.36	177.7
Net Cash (Debt)	-143.02	-221.64	-231.1	-154.15	-77.35	-100.67
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.37	-0.58	-0.56	-0.36	-0.17	-0.25

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Cash Flow	74.87	60.95	-40.83	11.64	25.22	23.55
Capital Expenditures	-47.61	-43.27	-24.91	-49.2	-32.98	-31.64
Free Cash Flow	27.26	17.68	-65.73	-37.56	-7.77	-8.09
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Gross Margin	49.83%	52.10%	51.56%	65.07%	65.55%	72.62%
Operating Margin	16.35%	6.27%	-41.20%	-15.61%	-16.10%	-15.49%
Pretax Margin	11.25%	2.95%	-60.95%	-30.93%	-3.23%	-12.60%
Profit Margin	14.69%	6.88%	-44.95%	-21.51%	3.28%	-6.35%
FCF Margin	9.10%	6.39%	-37.73%	-15.92%	-2.83%	-2.52%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
PE Ratio	74.17	151.56	-	-	334.55	-
Forward PE	-	18.69	18.69	18.69	18.69	18.69
P/FCF Ratio	130.06	163.27	-	-	-	-
PS Ratio	11.83	10.43	43.63	13.26	10.97	6.07